famotidine has been researched along with Ulcer in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two different doses of famotidine (20 mg twice a day versus 40 mg twice a day) were evaluated in a double-blind, randomized multicenter study in 474 symptomatic patients with erosive ulcerative reflux esophagitis." | 9.07 | Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. ( Dekker, W; Festen, HP; Wesdorp, IC, 1993) |
| "Two different doses of famotidine (20 mg twice a day versus 40 mg twice a day) were evaluated in a double-blind, randomized multicenter study in 474 symptomatic patients with erosive ulcerative reflux esophagitis." | 5.07 | Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. ( Dekker, W; Festen, HP; Wesdorp, IC, 1993) |
| " Future studies with famotidine in paediatrics should address its disposition in children under the age of 1 year and in children with compromised renal function, as well as the bioavailability of the oral formulation." | 2.39 | Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. ( James, LP; Kearns, GL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiratori, K | 1 |
| Watanabe, S | 1 |
| Maruyama, M | 1 |
| Adachi, H | 1 |
| Itoh, Y | 1 |
| Kurokawa, K | 1 |
| Takeuchi, T | 1 |
| Wesdorp, IC | 1 |
| Dekker, W | 1 |
| Festen, HP | 1 |
| James, LP | 1 |
| Kearns, GL | 1 |
| Sartori, S | 1 |
| Nielsen, I | 1 |
| Maestri, A | 1 |
| Beltrami, D | 1 |
| Trevisani, L | 1 |
| Pazzi, P | 1 |
1 review available for famotidine and Ulcer
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Child; Child, Preschool; Famotidine; Gastric Acid; Gastric Muc | 1996 |
1 trial available for famotidine and Ulcer
| Article | Year |
|---|---|
Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Esoph | 1993 |
2 other studies available for famotidine and Ulcer
| Article | Year |
|---|---|
[A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
Topics: Chronic Disease; Esophageal Diseases; Esophagogastric Junction; Famotidine; Histamine H2 Antagonists | 1984 |
Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy. Clinical and endoscopic study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endoscopy; Etoposide; Famotidine; | 1991 |